

MARKET FOR PET RADIOPHARMACEUTICALS AND PET IMAGING

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.0	PET MARKET OVERVIEW	1
1.1	Positive Growth Environment for PET	2
1.2	Changes in Utilization of PET	4
1.2.1	Increased PET Utilization with Greater Efficiency	6
1.2.2	Changes in the Product Mix of PET Scanners	6
1.3	Changes in PET Reimbursement	7
1.3.1	Coverage Uncertainties	8
1.3.2	Changes in the Allowable PET Scans	9
1.3.3	Approval of Multiple PET Scans	11
1.3.4	Active or Pending PET Registries (NOPR's)	11
1.3.5	Impact of PET in Reducing Biopsies	13
1.4	Prospects for Expanding the Use of PET in Oncology	13
1.4.1	Changing the Mindset of PET Users	14
1.4.2	The Issue of Segmenting PET into Body Parts for Diagnosis	15
1.4.3	Recent Relaxation in Some of the Rules	16
1.5	Reimbursement for New PET Radiopharmaceuticals	17
1.5.1	Coverage Options	18
1.5.2	Equivalency with Other Specialized Products	19

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.6	The Road Toward Open Coverage for PET	20
1.7	Growth of Primary Applications for PET in Oncology	21
1.7.1	Therapy Planning and Treatment Monitoring	22
1.7.2	Expanded Applications for PET in Oncology	24
1.7.3	PET Scanning for Prostate Cancer	25
1.7.4	Bone Scanning with Sodium Fluoride	25
1.7.5	Infection Imaging	26
1.7.6	The Naviscan PEM Breast Imaging System	27
1.8	Prospects for Growth of Cardiac PET	28
1.8.1	Changing Reimbursement	28
1.8.2	Cardiology PET Scanner Requirements	29
1.8.3	Myocardial Viability Imaging with FDG	30
1.8.4	The Successful Introduction of PET-MR	30
1.9	Prospects for Integrating Diagnostic CT with PET-CT	31
1.9.1	Advantages of Simultaneous Diagnostic CT and PET	32
1.9.2	More Technology and Support Required	32
1.9.3	Artifacts Introduced	33
1.9.4	Overlap of CT Contrast and FDG	34
2.0	New PET Tracers and Biomarkers	35
2.1	New Products for Diagnosing Alzheimer's Disease	36
2.1.1	Avid Radiopharmaceuticals' Amyvid	38
2.1.2	PETNet Solutions to Manufacture and Distribute Amyvid	38

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
	2.1.3 Other Alzheimer's Products in the Pipeline	39
	2.1.4 Two Potential Areas for Amyloid Imaging	40
2.2	New PET Agents and Methodologies for Cardiology	40
	2.2.1 Lantheus Enters Phase III with its Agent Flurpiridaz	41
	2.2.2 Flouro-Pharma's BFPET	42
	2.2.4 Neuronal Imaging Agents	43
2.3	New PET Biomarkers for Oncology	43
	2.3.1 Apoptosis Imaging	44
	2.3.2 Aposense ML-10	44
	2.3.3 Siemens' Apoptosis Imaging Agent	46
2.4	Integrin Peptides and Integrin Binding Agents	47
	2.4.1 Integrin Biomarker Developments	47
	2.4.2 Development Challenges with Integrin Products	48
	2.4.3 Interaction with Avastin and VEGF Signaling	48
2.5	Flucyclidine Amino Acid Metabolism	49
2.6	Imaging Hypoxia with PET	50
	2.6.1 Reimbursement Issues	51
	2.6.2 Not a First Line Therapy Approach	51
	2.6.3 Oncology Groups as Prospects for this Type of Therapy	52
	2.6.4 Other Options for Use of this Agent	52
	2.6.5 Challenge of Showing that HX4 is Better than FMISO	53

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
2.7	New Oncology Biomarkers Developed by NuView Life Sciences	53
2.7.1	NuView's Molecular Breast Cancer Probe	54
2.7.2	NuView's Cancer Biomarker for Cellular Proliferation (FMAU)	54
\3.0	GROWTH OF PET PROCEDURE VOLUME	55
3.1	Positive Growth Factors	56
3.2	Restraining Influences	57
3.3	Forecast Growth of PET Procedures	58
3.3.1	PET Cardiology Procedure Growth	61
3.3.2	PET Neurology Procedure Growth	62
3.3.3	PET Oncology Procedure Growth	63
3.4	Forecast Growth of PET Radiopharmaceutical Sales	64
3.4.1	Forecast Sales Growth of PET Cardiology Products	67
3.4.1.1	New PET Perfusion Agents	69
3.4.1.2	Continuing Growth for Rubidium	71
3.4.1.3	Neuronal Imaging Agents	71
3.4.2	Forecast Sales Growth of PET Neurology Products	73
3.4.3	Forecast Sales Growth of PET Oncology Products	75
3.4.3.1	Apoptosis Imaging	75
3.4.3.2	Angiogenesis Imaging	77
3.4.3.3	Other New Oncology Imaging Agents	78
3.5	Overlap Between PET and SPECT Imaging in Oncology	79
3.5.1	Experience with Targeted SPECT Agents for Oncology	79

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
3.5.2 Comparative Advantages of PET in Oncology	80
4.0 ANALYSIS OF THE FDG MARKET	81
4.1 FDG Pricing	82
4.2 Historic and Forecast Sales of FDG	83
4.3 Distribution of FDG Sales by Procedure Type	83
4.4 Economics of Producing and Delivering FDG Doses	84
4.5 Challenges in the Production and Distribution of FDG	85
4.6 Analysis of FDG Suppliers	86
4.6.1 PETNet Pharmaceuticals	88
4.6.2 Cardinal Health	89
4.6.3 IBA Molecular	90
4.6.4 Triad Pharmacies	91
4.6.5 Other Pharmacies and Academic Sites	91
5.0 MARKET FOR PET IMAGING EQUIPMENT	92
5.1 Market Overview	107
5.2 International Market Growth	107
5.3 Product Focus of PET Manufacturers	110
5.3.1 Siemens Molecular Imaging	110
5.3.2 GE Medical Systems	113
5.3.3 Philips Medical Systems	116
5.3.4 Naviscan, Inc.	119
5.4 U.S. and International Market for PET Scanners	121

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
	5.4.1 Domestic Market for New and Refurbished PET Scanners	121
	5.4.2 International Market for New and Refurbished PET scanners	123
5.5	Mobile PET Market	124
	5.5.1 Contractual Relationships Used by Mobile Providers	125
	5.5.2 Charges for Reading the Scans	126
	5.5.3 Reading the PET-CT Study	127
	5.5.4 Providers of Mobile PET Services	128
6.0	US AND WORLDWIDE SALES FORECASTS FOR PET	130
	6.1 US Sales Forecasts for PET Scanners	130
	6.2 Sales Forecast for Mobile PET Systems	139
	6.3 Worldwide Sales Forecast for PET scanners	140
7.0	CHANGES IN US AND WORLDWIDE INSTALLED BASE	142
	7.1 Growth of U.S. and Worldwide Installed Base of PET Scanners	142
	7.2 Growth of Installed Base of Mobile Scanners	142
	7.3 Estimated PET Procedure Volume Based on Scanner Utilization	145
8.0	END-USER PROFILE	147
	8.1 Overview of the User Environment	147
	8.2 Organization of Nuclear Medicine Departments	148
	8.2.1 Important Functional Differences with PET	149
	8.2.2 Interaction of PET with Radiology	150
	8.3 Allocation of Hospital Nuclear Medicine Equipment	151
	8.4 Comparative Utilization Parameters	153

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>	
	8.4.1	Distribution of Imaging Procedures	153
	8.4.2	Relative Diagnostic Activity	155
	8.4.3	Relative Procedure Volume	155
	8.4.4	Imaging Activity Index	158
8.5		In-Hospital Hot Lab Versus Commercial Pharmacies	160
	8.5.1	Unit-Dose Packaging	161
	8.5.2	Pricing Practices	162
	8.5.3	Other Services	162
	8.5.4	Issues of Board Certification	163

**MARKET FOR PET RADIOPHAMACEUTICALS
AND PET IMAGING**

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
1	HISTORIC AND FORECAST PET PROCEDURE VOLUME FOR CARDIOLOGY, NEUROLOGY AND ONCOLOGY BY PROCEDURE TYPE FROM 2006-2018	60
2	HISTORIC AND FORECAST FDG PET PROCEDURE VOLUME IN ONCOLOGY BY TYPE OF DISEASE FROM 2005-2018	65
3	HISTORIC AND FORECAST SALES OF FDG FOR ONCOLOGY BY DISEASE TYPE FROM 2006-2018	66
4	HISTORIC AND FORECAST SALES SUMMARY FOR PET RADIADIOPHAMACEUTICALS BY APPLICATION FOR CADIOLOGY, NEUROLOGY AND ONCOLOGY FROM 2006-2018	68
5	HISTORIC AND FORECAST SALES OF PET CARDIOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2004-2018	70
6	HISTORIC AND FORECAST SALES OF RUBIDIUM GENERATORS FOR CADIOLOGY PET PERFUSION STUDIES FROM 2005-2018	72
7	HISTORIC AND FORECAST SALES OF PET NEUROLOGY IMAGING PRODUCTS BY PRODUCT CATEGORY FROM 2006-2018	74
8	HISTORIC AND FORECAST SALES GROWTH OF PET ONCOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2018	76
9	SALES OF FDG SUPPLIERS IN THE U.S. IN 2010 AND FIRST HALF OF 2011, NUMBER OF PET PHARMACIES, ANNUAL DOSES SOLD AND SALES VOLUME	87
10	U.S. UNIT ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	93
11	U.S. ORDER VOLUME FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME PET BY MANUFACTURER AND MARKET SHARE	94

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
12	HISTORIC U.S. UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009 PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	95
13	HISTORIC U.S. SALES OF PET SCANNERS IN 2008 AND 2009 SALES VOLUME BY MANUFACTURERS AND MARKET SHARE	96
14	INTERNATIONAL ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	97
15	INTERNATIONAL SALES OF PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	98
16	HISTORIC INTERNATIONAL UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	99
17	HISTORIC INTERNATIONAL SALES OF PET SCANNERS IN 2008 AND 2009, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	100
18	WORLDWIDE UNIT ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	101
19	WORLDWIDE SALES OF PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	102
20	HISTORIC WORLDWIDE UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	103
21	HISTORIC WORLDWIDE SALES OF PET SCANNERS IN 2008 AND 2009, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	104
22	U.S. UNIT ORDERS FOR MOBILE PET SCANNERS FROM 2008-2010, UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	105
23	U.S. SALES OF MOBILE PET SCANNERSVFROM 2008-2010, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	106
24	PET UNITS PURCHASED BY MOBILE PET PROVIDERS FROM 2000-2010, UNITS ACQUIRED BY EACH MOBILE PET COMPANY	129

4LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
25	HISTORIC AND FORECAST U.S. UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	131
26	HISTORIC AND FORECAST U.S. SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	132
27	HISTORIC AND FORECAST U.S. ORDERS OF MOBILE PET SCANNERS, MANUFACTURERS' UNIT ORDERS AND SALES VOLUME FROM 2005-2018	133
28	HISTORIC AND FORECAST INTERNATIONAL UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	134
29	HISTORIC AND FORECAST INTERNATIONAL SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	135
30	HISTORIC AND FORECAST WORLDWIDE UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	136
31	HISTORIC AND FORECAST WORLDWIDE SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	137
32	GROWTH OF U.S. AND WORLDWIDE INSTALLED BASE OF PET SCANNERS FROM 2005-2018	143
33	GROWTH OF MOBILE PET INSTALLED BASE IN THE U.S. FROM 2005-2018	144
34	ESTIMATED PET PROCEDURE VOLUME IN THE U.S. BASED ON SCANNER UTILIZATION IN 2010	146
35	COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2010	152
36	COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2010	154
37	DISTRIBUTION OF HOSPITAL DIAGNOSTIC IMAGING PROCEDURES IN THE U.S. BY HOSPITAL BED SIZE IN 2009	156

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
38	RELATIVE PROCEDURE VOLUME AMONG DIFFERENT IMAGING MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2010	157
39	RELATIVE ACTIVITY INDEX AMONG DIFFERENT IMAGING MODALITIES, PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2010	159

MARKET FOR PET RADIOPHARMACEUTICALS AND PET IMAGING

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.0	PET MARKET OVERVIEW	1
1.1	Positive Growth Environment for PET	2
1.2	Changes in Utilization of PET	4
1.2.1	Increased PET Utilization with Greater Efficiency	6
1.2.2	Changes in the Product Mix of PET Scanners	6
1.3	Changes in PET Reimbursement	7
1.3.1	Coverage Uncertainties	8
1.3.2	Changes in the Allowable PET Scans	9
1.3.3	Approval of Multiple PET Scans	11
1.3.4	Active or Pending PET Registries (NOPR's)	11
1.3.5	Impact of PET in Reducing Biopsies	13
1.4	Prospects for Expanding the Use of PET in Oncology	13
1.4.1	Changing the Mindset of PET Users	14
1.4.2	The Issue of Segmenting PET into Body Parts for Diagnosis	15
1.4.3	Recent Relaxation in Some of the Rules	16
1.5	Reimbursement for New PET Radiopharmaceuticals	17
1.5.1	Coverage Options	18
1.5.2	Equivalency with Other Specialized Products	19

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.6	The Road Toward Open Coverage for PET	20
1.7	Growth of Primary Applications for PET in Oncology	21
1.7.1	Therapy Planning and Treatment Monitoring	22
1.7.2	Expanded Applications for PET in Oncology	24
1.7.3	PET Scanning for Prostate Cancer	25
1.7.4	Bone Scanning with Sodium Fluoride	25
1.7.5	Infection Imaging	26
1.7.6	The Naviscan PEM Breast Imaging System	27
1.8	Prospects for Growth of Cardiac PET	28
1.8.1	Changing Reimbursement	28
1.8.2	Cardiology PET Scanner Requirements	29
1.8.3	Myocardial Viability Imaging with FDG	30
1.8.4	The Successful Introduction of PET-MR	30
1.9	Prospects for Integrating Diagnostic CT with PET-CT	31
1.9.1	Advantages of Simultaneous Diagnostic CT and PET	32
1.9.2	More Technology and Support Required	32
1.9.3	Artifacts Introduced	33
1.9.4	Overlap of CT Contrast and FDG	34
2.0	New PET Tracers and Biomarkers	35
2.1	New Products for Diagnosing Alzheimer's Disease	36
2.1.1	Avid Radiopharmaceuticals' Amyvid	38
2.1.2	PETNet Solutions to Manufacture and Distribute Amyvid	38

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
	2.1.3 Other Alzheimer's Products in the Pipeline	39
	2.1.4 Two Potential Areas for Amyloid Imaging	40
2.2	New PET Agents and Methodologies for Cardiology	40
	2.2.1 Lantheus Enters Phase III with its Agent Flurpiridaz	41
	2.2.2 Flouro-Pharma's BFPET	42
	2.2.4 Neuronal Imaging Agents	43
2.3	New PET Biomarkers for Oncology	43
	2.3.1 Apoptosis Imaging	44
	2.3.2 Aposense ML-10	44
	2.3.3 Siemens' Apoptosis Imaging Agent	46
2.4	Integrin Peptides and Integrin Binding Agents	47
	2.4.1 Integrin Biomarker Developments	47
	2.4.2 Development Challenges with Integrin Products	48
	2.4.3 Interaction with Avastin and VEGF Signaling	48
2.5	Flucyclidine Amino Acid Metabolism	49
2.6	Imaging Hypoxia with PET	50
	2.6.1 Reimbursement Issues	51
	2.6.2 Not a First Line Therapy Approach	51
	2.6.3 Oncology Groups as Prospects for this Type of Therapy	52
	2.6.4 Other Options for Use of this Agent	52
	2.6.5 Challenge of Showing that HX4 is Better than FMISO	53

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
2.7	New Oncology Biomarkers Developed by NuView Life Sciences	53
2.7.1	NuView's Molecular Breast Cancer Probe	54
2.7.2	NuView's Cancer Biomarker for Cellular Proliferation (FMAU)	54
\3.0	GROWTH OF PET PROCEDURE VOLUME	55
3.1	Positive Growth Factors	56
3.2	Restraining Influences	57
3.3	Forecast Growth of PET Procedures	58
3.3.1	PET Cardiology Procedure Growth	61
3.3.2	PET Neurology Procedure Growth	62
3.3.3	PET Oncology Procedure Growth	63
3.4	Forecast Growth of PET Radiopharmaceutical Sales	64
3.4.1	Forecast Sales Growth of PET Cardiology Products	67
3.4.1.1	New PET Perfusion Agents	69
3.4.1.2	Continuing Growth for Rubidium	71
3.4.1.3	Neuronal Imaging Agents	71
3.4.2	Forecast Sales Growth of PET Neurology Products	73
3.4.3	Forecast Sales Growth of PET Oncology Products	75
3.4.3.1	Apoptosis Imaging	75
3.4.3.2	Angiogenesis Imaging	77
3.4.3.3	Other New Oncology Imaging Agents	78
3.5	Overlap Between PET and SPECT Imaging in Oncology	79
3.5.1	Experience with Targeted SPECT Agents for Oncology	79

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
3.5.2 Comparative Advantages of PET in Oncology	80
4.0 ANALYSIS OF THE FDG MARKET	81
4.1 FDG Pricing	82
4.2 Historic and Forecast Sales of FDG	83
4.3 Distribution of FDG Sales by Procedure Type	83
4.4 Economics of Producing and Delivering FDG Doses	84
4.5 Challenges in the Production and Distribution of FDG	85
4.6 Analysis of FDG Suppliers	86
4.6.1 PETNet Pharmaceuticals	88
4.6.2 Cardinal Health	89
4.6.3 IBA Molecular	90
4.6.4 Triad Pharmacies	91
4.6.5 Other Pharmacies and Academic Sites	91
5.0 MARKET FOR PET IMAGING EQUIPMENT	92
5.1 Market Overview	107
5.2 International Market Growth	107
5.3 Product Focus of PET Manufacturers	110
5.3.1 Siemens Molecular Imaging	110
5.3.2 GE Medical Systems	113
5.3.3 Philips Medical Systems	116
5.3.4 Naviscan, Inc.	119
5.4 U.S. and International Market for PET Scanners	121

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
	5.4.1 Domestic Market for New and Refurbished PET Scanners	121
	5.4.2 International Market for New and Refurbished PET scanners	123
5.5	Mobile PET Market	124
	5.5.1 Contractual Relationships Used by Mobile Providers	125
	5.5.2 Charges for Reading the Scans	126
	5.5.3 Reading the PET-CT Study	127
	5.5.4 Providers of Mobile PET Services	128
6.0	US AND WORLDWIDE SALES FORECASTS FOR PET	130
	6.1 US Sales Forecasts for PET Scanners	130
	6.2 Sales Forecast for Mobile PET Systems	139
	6.3 Worldwide Sales Forecast for PET scanners	140
7.0	CHANGES IN US AND WORLDWIDE INSTALLED BASE	142
	7.1 Growth of U.S. and Worldwide Installed Base of PET Scanners	142
	7.2 Growth of Installed Base of Mobile Scanners	142
	7.3 Estimated PET Procedure Volume Based on Scanner Utilization	145
8.0	END-USER PROFILE	147
	8.1 Overview of the User Environment	147
	8.2 Organization of Nuclear Medicine Departments	148
	8.2.1 Important Functional Differences with PET	149
	8.2.2 Interaction of PET with Radiology	150
	8.3 Allocation of Hospital Nuclear Medicine Equipment	151
	8.4 Comparative Utilization Parameters	153

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>	
	8.4.1	Distribution of Imaging Procedures	153
	8.4.2	Relative Diagnostic Activity	155
	8.4.3	Relative Procedure Volume	155
	8.4.4	Imaging Activity Index	158
8.5		In-Hospital Hot Lab Versus Commercial Pharmacies	160
	8.5.1	Unit-Dose Packaging	161
	8.5.2	Pricing Practices	162
	8.5.3	Other Services	162
	8.5.4	Issues of Board Certification	163

**MARKET FOR PET RADIOPHAMACEUTICALS
AND PET IMAGING**

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
1	HISTORIC AND FORECAST PET PROCEDURE VOLUME FOR CARDIOLOGY, NEUROLOGY AND ONCOLOGY BY PROCEDURE TYPE FROM 2006-2018	60
2	HISTORIC AND FORECAST FDG PET PROCEDURE VOLUME IN ONCOLOGY BY TYPE OF DISEASE FROM 2005-2018	65
3	HISTORIC AND FORECAST SALES OF FDG FOR ONCOLOGY BY DISEASE TYPE FROM 2006-2018	66
4	HISTORIC AND FORECAST SALES SUMMARY FOR PET RADIADIOPHAMACEUTICALS BY APPLICATION FOR CADIOLOGY, NEUROLOGY AND ONCOLOGY FROM 2006-2018	68
5	HISTORIC AND FORECAST SALES OF PET CARDIOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2004-2018	70
6	HISTORIC AND FORECAST SALES OF RUBIDIUM GENERATORS FOR CADIOLOGY PET PERFUSION STUDIES FROM 2005-2018	72
7	HISTORIC AND FORECAST SALES OF PET NEUROLOGY IMAGING PRODUCTS BY PRODUCT CATEGORY FROM 2006-2018	74
8	HISTORIC AND FORECAST SALES GROWTH OF PET ONCOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2018	76
9	SALES OF FDG SUPPLIERS IN THE U.S. IN 2010 AND FIRST HALF OF 2011, NUMBER OF PET PHARMACIES, ANNUAL DOSES SOLD AND SALES VOLUME	87
10	U.S. UNIT ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	93
11	U.S. ORDER VOLUME FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME PET BY MANUFACTURER AND MARKET SHARE	94

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
12	HISTORIC U.S. UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009 PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	95
13	HISTORIC U.S. SALES OF PET SCANNERS IN 2008 AND 2009 SALES VOLUME BY MANUFACTURERS AND MARKET SHARE	96
14	INTERNATIONAL ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	97
15	INTERNATIONAL SALES OF PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	98
16	HISTORIC INTERNATIONAL UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	99
17	HISTORIC INTERNATIONAL SALES OF PET SCANNERS IN 2008 AND 2009, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	100
18	WORLDWIDE UNIT ORDERS FOR PET SCANNERS IN 2010 AND FIRST HALF OF 2011, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	101
19	WORLDWIDE SALES OF PET SCANNERS IN 2010 AND FIRST HALF OF 2011, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	102
20	HISTORIC WORLDWIDE UNIT ORDERS FOR PET SCANNERS IN 2008 AND 2009, PET UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	103
21	HISTORIC WORLDWIDE SALES OF PET SCANNERS IN 2008 AND 2009, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	104
22	U.S. UNIT ORDERS FOR MOBILE PET SCANNERS FROM 2008-2010, UNITS ORDERED BY MANUFACTURER AND MARKET SHARE	105
23	U.S. SALES OF MOBILE PET SCANNERSVFROM 2008-2010, SALES VOLUME BY MANUFACTURER AND MARKET SHARE	106
24	PET UNITS PURCHASED BY MOBILE PET PROVIDERS FROM 2000-2010, UNITS ACQUIRED BY EACH MOBILE PET COMPANY	129

4LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
25	HISTORIC AND FORECAST U.S. UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	131
26	HISTORIC AND FORECAST U.S. SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	132
27	HISTORIC AND FORECAST U.S. ORDERS OF MOBILE PET SCANNERS, MANUFACTURERS' UNIT ORDERS AND SALES VOLUME FROM 2005-2018	133
28	HISTORIC AND FORECAST INTERNATIONAL UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	134
29	HISTORIC AND FORECAST INTERNATIONAL SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	135
30	HISTORIC AND FORECAST WORLDWIDE UNIT ORDERS FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	136
31	HISTORIC AND FORECAST WORLDWIDE SALES VOLUME FOR NEW AND REFURBISHED PET SCANNERS FROM 2005-2018	137
32	GROWTH OF U.S. AND WORLDWIDE INSTALLED BASE OF PET SCANNERS FROM 2005-2018	143
33	GROWTH OF MOBILE PET INSTALLED BASE IN THE U.S. FROM 2005-2018	144
34	ESTIMATED PET PROCEDURE VOLUME IN THE U.S. BASED ON SCANNER UTILIZATION IN 2010	146
35	COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2010	152
36	COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2010	154
37	DISTRIBUTION OF HOSPITAL DIAGNOSTIC IMAGING PROCEDURES IN THE U.S. BY HOSPITAL BED SIZE IN 2009	156

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
38	RELATIVE PROCEDURE VOLUME AMONG DIFFERENT IMAGING MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2010	157
39	RELATIVE ACTIVITY INDEX AMONG DIFFERENT IMAGING MODALITIES, PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2010	159